Sprycel (dasatinib, Bristol-Myers Squibb) by Ray Sahelian, M.D.

Sprycel (dasatinib, Bristol-Myers Squibb) is an oral inhibitor of multiple tyrosine kinases approved by the FDA for the treatment of adults in all phases of chronic myeloid leukemia (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy, including Gleevec (imatinib mesylate).

For more info on prescription medications.